W
Wendy Wieland-Alter
Researcher at Dartmouth–Hitchcock Medical Center
Publications - 37
Citations - 1245
Wendy Wieland-Alter is an academic researcher from Dartmouth–Hitchcock Medical Center. The author has contributed to research in topics: Antibody & Poliovirus. The author has an hindex of 18, co-authored 34 publications receiving 882 citations. Previous affiliations of Wendy Wieland-Alter include Dartmouth College & Muhimbili University of Health and Allied Sciences.
Papers
More filters
Journal ArticleDOI
Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
Elizabeth B. Brickley,Wendy Wieland-Alter,Ruth I Connor,Margaret E. Ackerman,Austin W. Boesch,Minetaro Arita,William C. Weldon,M O'Ryan,Ananda S Bandyopadhyay,Peter F. Wright +9 more
TL;DR: Results underscore the concept that mucosal and systemic immune responses to polio are separate in their induction, functionality, and potential impacts on transmission and provide evidence that primary vaccine regimens lacking homologous live vaccine components are likely to induce only modest, type-specific intestinal immunity.
Journal ArticleDOI
Systematic comparison of respiratory syncytial virus-induced memory B cell responses in two anatomical compartments.
Laila Shehata,Wendy Wieland-Alter,Daniel P. Maurer,Eunice Y. Chen,Ruth I Connor,Peter F. Wright,Laura M. Walker +6 more
TL;DR: The authors isolate over 800 RSV F-specific antibodies from paired nasopharyngeal tonsil and peripheral blood samples from four young children undergoing adenoidectomy and find that adenoids derived antibodies have overall higher binding affinities and neutralization potencies.
Journal ArticleDOI
A Randomized Phase 4 Study of Immunogenicity and Safety After Monovalent Oral Type 2 Sabin Poliovirus Vaccine Challenge in Children Vaccinated with Inactivated Poliovirus Vaccine in Lithuania.
Ananda S Bandyopadhyay,Chris Gast,Elizabeth B. Brickley,Ricardo Rüttimann,Ralf Clemens,M. Steven Oberste,William C. Weldon,Margaret E. Ackerman,Ruth I Connor,Wendy Wieland-Alter,Peter F. Wright,Vytautas Usonis +11 more
TL;DR: High viral excretion following mOPV2 among exclusively IPV-vaccinated children was substantially lower following a subsequent dose, indicating induction of intestinal immunity against type-2 poliovirus.
Journal ArticleDOI
Intestinal antibody responses to two novel live attenuated type 2 oral poliovirus vaccines in healthy adults in Belgium.
Elizabeth B. Brickley,Ruth I Connor,Wendy Wieland-Alter,Joshua A. Weiner,Margaret E. Ackerman,Minetaro Arita,Chris Gast,Ilse De Coster,Pierre Van Damme,Ananda S Bandyopadhyay,Peter F. Wright +10 more
TL;DR: In a blinded phase 1 trial (EudraCT 2017-0000908-21; NCT03430349) in Belgium, healthy adults (18 to 50 years) previously immunized exclusively with inactivated polio vaccine were administered a single dose of one of two novel type 2 oral polio vaccines (nOPV2-c1: S2/cre5/S15domV/rec1/hifi3 (N=15); nOPV 2c2: S 2/S 15dom V/CpG40 (N = 15)) and
Journal ArticleDOI
Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike
Andrew R. Crowley,Harini Natarajan,Andrew P. Hederman,Carly A. Bobak,Joshua A. Weiner,Wendy Wieland-Alter,Jiwon Lee,Evan M. Bloch,Aaron A.R. Tobian,Andrew D. Redd,Joel N. Blankson,Dana G. Wolf,Tessa Goetghebuer,Arnaud Marchant,Ruth I. Connor,Peter F. Wright,Margaret E. Ackerman +16 more
TL;DR: Evidence is provided that antibodies targeting endemic CoV are robustly boosted in response to SARS-CoV-2 infection but not to vaccination with stabilized S, and that depending on conformation or other factors, the S2 subdomain of the spike protein triggers a rapidly recalled, IgG-dominated response that lacks neutralization activity.